OhioHealth

What it reported doing in 2024

The OhioHealth Research Institute (OHRI) is committed to providing the resources needed to advance patient care through clinical research and innovation. As one of the top 10 percent of research programs at non-profit, community-based healthcare systems, our program is a leader in researching new drugs, medical devices and procedures. Our access to leading edge clinical trials allows us to deliver improved outcomes and potentially save lives by giving our patients access to the therapies of the future today. OhioHealth's emphasis on research reflects our commitment to the community, our clinicians and, most of all, our patients. Our clinicians generate and pursue research and innovation ideas from their real-world experience caring for patients. We view clinical research as an extension of clinical care because it allows our physicians, nurses and other clinicians to provide leading-edge treatments to patients. Our areas of focus are industry research that expands patient access to groundbreaking clinical trials. These trials pave the way for better treatments. OHRI welcomes industry-sponsored research in partnership with drug and device companies looking to test their investigational products at a large facility associated with excellent clinicians. Academic research focuses on educating and training our physicians and clinicians with programs that develop their skills, knowledge and leadership in advancing healthcare. OhioHealth also provides an ideal setting for federal and foundation funded research that addresses the needs of the public. Innovation and commercialization supports OhioHealth physicians, clinicians and medical staff with their innovative ideas. Through its OhioHealth $5 million Innovation Development Fund, OHRI provides financial support and resources in all stages of product development and commercialization with the ultimate goal of improving patient care. Sponsored programs are initiatives that are funded by grant monies. Our finance experts have extensive experience in managing and reporting grant monies needed to fund important initiatives. Health equity programs bring healthcare programs and services to underserved communities and people such as Latina women, Amish and Mennonite communities, teenage mothers and the Appalachian region. The OhioHealth Research Institute is vital to OhioHealth's recognition as a national leader in developing and advancing medical breakthroughs as well as meeting the needs of our community. Our Successes are 19 Years of Improving Care: Transcatheter Aortic Valve Replacement OhioHealth has been on the forefront of revolutionizing care for patients with aortic valve disease by leading successful clinical trials since 2006. In fact, our work has been integral in the FDA-approval of transcatheter aortic valve devices now being used to treat patients with aortic valve disease who had no other treatment options. MD Anderson Cancer Network As part of OhioHealth's collaboration with the MD Anderson Cancer Network, we are now participating in cancer clinical trials through the University of Texas MD Anderson Cancer Center. Research across the region As our hospital system has continued to expand across the state, so have our research programs. We now offer clinical research at many of our outlying hospitals including OhioHealth Mansfield Hospital. First in human clinical trials For many years, most first in human clinical research trials have been conducted outside of the United States. However, a new concerted effort by the FDA to bring these leading-edge trials back to the US has landed OhioHealth two first in human clinical trials in the past years - one of only three health systems in the country to achieve this due to our proven track record of leading safe and successful clinical trials. Meeting the needs of the underserved Through our health equity programs, we have provided access to care to many underserved communities including Appalachian, the Amish and Mennonite, Latina

Financial Efficiency

• Mission deployment rate: 95.3%; rating input score 95
• Program expense ratio: 78.4%; rating input score 78
• Fundraising efficiency: $3.17 raised per $1 spent on fundraising; rating input score 11; 11th percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
• Pay-setting controls: 1 of 6 controls in place; rating input score 17
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 77th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 71.2%; rating input score 71; 21st percentile among comparable filings
• Governance controls: 6 of 9 controls in place; rating input score 75
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Limited
  • Other executive compensation review process: Fail
  • Form 990 shared with the board: Fail
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -13.6%; rating input score 6; 6th percentile among comparable filings
• Total-asset coverage ratio: 0.76; rating input score 30; 30th percentile among comparable filings
• Liabilities to assets ratio: 0.43; rating input score 42; 42nd percentile among comparable filings
• Officer compensation ratio: 0.8%; rating input score 79; 79th percentile among comparable filings

Growth

• Program expense growth: 8.4% per year; rating input score 100; 66th percentile among comparable filings
• Revenue growth: 9.9% per year; rating input score 100; 76th percentile among comparable filings
• Asset growth: 8.8% per year; rating input score 100; 64th percentile among comparable filings